DiaMedica Therapeutics DMAC
NASDAQ DMAC
$6.44 -0.15 (-2.28%)
As of: Sep 10, 2026 · 11:40 AM EDT

DiaMedica Therapeutics (DMAC) Interest Expenses (2024 - 2026)

DiaMedica Therapeutics' (DMAC) quarterly Interest Expenses came in at $23000.0 in Q1 2026, up 2200.0% on a YoY basis from $1000.0 in Q1 2025, and up 2200.0% quarter-over-quarter from $1000.0 in Q1 2025.

Analysis

DiaMedica Therapeutics (DMAC) Interest Expenses (2024 - 2026) Analysis & Trends

DiaMedica Therapeutics (DMAC) has reported Interest Expenses for 3 consecutive years, with $23000.0 the latest figure, recorded in Q1 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Expense (Qtr)
1 Amgen 206.86 Bn 192.87 Bn 7.24 Bn 673.00 Mn
2 Gilead Sciences 179.52 Bn 176.34 Bn 6.22 Bn 247.00 Mn
3 Vertex Pharmaceuticals 131.47 Bn 123.62 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 11.00 Mn
5 Argenx Se 61.16 Bn 55.98 Bn 1.37 Bn -1.00 Mn
6 Moderna 53.15 Bn 48.02 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 33.20 Bn 29.89 Bn 992.69 Mn 82.05 Mn
8 Biogen 31.65 Bn 30.37 Bn 1.96 Bn -
9 Roivant Sciences 29.30 Bn 29.30 Bn 1.16 Mn -
10 DiaMedica Therapeutics 346.54 Mn 346.54 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 23,000.00
Mar 31, 2025 1,000.00
Mar 31, 2024 19,000.00